刘 强,郑秀惠,易 萍.卵巢癌术后多西他赛静脉加卡铂腹腔灌注和静脉二阶段联合化疗研究[J].肿瘤学杂志,2013,19(2):99-101.
卵巢癌术后多西他赛静脉加卡铂腹腔灌注和静脉二阶段联合化疗研究
Docetaxel Plus Carboplatin 2 Stage Administration with Itraperitoneal or Intravenous in Patients with Ovarian Cancer Postoperation
投稿时间:2012-10-08  
DOI:10.11735/j.issn.1671-170X.2013.02.B2012505
中文关键词:  卵巢肿瘤  多西他赛  卡铂  腹腔灌注  药物疗法
英文关键词:ovarian neoplasms  docetaxel  carboplatin  intraperitoneal chemotherapy  drug therapy
基金项目:第三军医大学校管课题(2007校管xg063)
作者单位
刘 强 第三军医大学大坪医院野战外科研究所 
郑秀惠 第三军医大学大坪医院野战外科研究所 
易 萍 第三军医大学大坪医院野战外科研究所 
摘要点击次数: 1891
全文下载次数: 1097
中文摘要:
      摘 要:[目的] 探讨卵巢癌术后多西他赛静脉加卡铂腹腔灌注、静脉二阶段联合化疗的疗效和安全性。[方法] 52例卵巢癌术后患者多西他赛75mg/m2静脉滴注 d1,卡铂按AUC=5计算 d1,前3个周期予腹腔内灌注,后3个周期予静脉滴注,d2、d3水化2d,21d为1个周期。连用2个周期后进行CA125影像学检查,评价疗效和观察不良反应。 [结果] 平均3.8个周期CA125下降至正常,腹水有效率(RR)为86.2%,实体瘤RR为88.5%。常见不良反应为骨髓抑制、恶心呕吐、脱发、腹泻、口腔黏膜炎和肌肉关节痛等。 [结论] 卵巢癌术后患者采用多西他赛静脉加卡铂腹腔灌注、静脉二阶段联合化疗疗效肯定,且不良反应可以耐受。
英文摘要:
      Abstract:[Purpose] To investigate the efficacy and safety of combination of intravenous docetaxel and carboplatin two-stage treatment with intraperitoneal or intravenous administration in patients with ovarian cancer postoperation.[Methods] A total of 52 postoperative ovarian cancer patients received chemotherapy. A treatment of 21 days was defined as a cycle. Docetaxel was administered at a dose of 75 mg/m2 iv. on day 1 and carboplatin according to AUC=5, ip. on day 1 in the first 3 cycles and iv. in the next 3 cycles .Hydration were performed on day 2 and 3 for 2 days in each cycle. CA125 testing and imaging inspection were performed after continuously treatments for 2 cycles to evaluate the efficacy and toxicities. [Results] The value of CA125 dropped to normal level after an average of 3.8 cycles’ treatment. The short-term response rate(RR) for ascites was 86.2% and that for solid tumors was 88.5%. The common toxicities were bone marrow suppression ,nausea,vomiting,alopecia,diarrhea,oral mucositis,muscle and joint pain. [Conclusion] The two-stage postoperative chemotherapy with combination of docetaxel and carboplatin is effective and tolerable in patients with ovarian cancer.
在线阅读   查看全文  查看/发表评论  下载PDF阅读器